

# High-level expression and purification of recombinant human Apolipoprotein A-I in *Pichia pastoris*

JANAKIRAMAN Vignesh<sup>1,2</sup>, NOUBHANI Majid<sup>1</sup>, VENKATARAMAN Krishnan<sup>2</sup>, SANTARELLI Xavier<sup>1</sup>

<sup>1</sup>EA4135 - ENSTBB/IPB, Université Bordeaux Segalen, 33076 Bordeaux, FRANCE



<sup>2</sup>CBST, VIT University, Vellore 632014, INDIA

**ABSTRACT.** The High Density Lipoprotein (HDL) complex, commonly addressed as the “good cholesterol” helps reduce the risk of cardiovascular disorders mainly due to its ability to remove accumulated cholesterol from arteries (via reverse cholesterol transport), in addition to possessing anti-inflammatory and anti-thrombotic properties. These protective effects of HDL are mediated mainly by Apolipoprotein A-I (ApoA1) which is the major protein component of HDL. ApoA1 is a lipid binding protein and promotes cholesterol efflux from peripheral tissues to the liver for excretion. An increase in the plasma levels of ApoA1 is generally accepted to be cardioprotective, making it a potential therapeutic. However, recombinant ApoA1 is rapidly cleared from the plasma and is also prone to oxidation by myeloperoxidase.

Two naturally occurring variants of ApoA1, namely the Milano & Paris mutants, are characterised by a single point mutation resulting in the introduction of a Cysteine residue. Populations with ApoA1-Milano have been reported to have a healthier cardiovascular system even with low plasma levels of ApoA1/HDL. Functional comparison of native and mutant ApoA1 variants would enhance our understanding of their mechanisms of action. In this study, we present a method that has been streamlined to facilitate high-level secreted expression of recombinant human ApoA1 in its native form (without the use of any affinity tag) by the methylotrophic yeast *Pichia pastoris* in a bioreactor, followed by a comparison of several purification methods (two-phase extraction, cold acetone precipitation, ion-exchange chromatography and mixed-mode chromatography) to efficiently recover the protein with highest efficiency. This process would not only yield the protein with maximum functionality, but also promises immense industrial implications.

## Apolipoprotein A-I (ApoA1)

- Major protein component of HDL
- Key effector functions:
  - Uptake of cholesterol and phospholipids from tissues
  - Activation of LCAT
- Plethora of variants




Source: Lipids Online Slide Library


## rhApoA1 expression

Host Organism: *Pichia pastoris* Induction of Expression: Methanol, 0.5% Duration of Induction: 5 days (120hrs)


Expression profile (2l bioreactor):




Protein expression:



## rhApoA1 purification




Cloud point extraction:




## Ion-Exchange Chromatography:

Strategy:




- Protein recovered in high concentration
- Aggregates observed
- Lengthy sample pretreatment required
- Not suitable for scaling up

## Cold-acetone precipitation:



- Large quantities of cold acetone required
- Long incubation times at sub-zero temperatures
- Not suitable for scale up

## Mixed-mode chromatography:



## Conclusion

High-level expression of rhApoA1 with *Pichia pastoris* without the use of affinity tags.

Single-step purification of rhApoA1 from the broth using Mixed-Mode chromatography without any pretreatment, while maintaining the integrity of the protein for future functional applications.

Direct industrial application in cost-effective production of therapeutic rhApoA1.

## ACKNOWLEDGEMENTS

Ministère des Affaires étrangères (Gouvernement français) for Bourse d'Excellence Eiffel

University Grants Commission (Govt. of India) for Junior Research Fellowship

Region Aquitaine and Dept. of Science & Technology (Govt. of India) for financial support